Liquid Biopsy Promising for Surveillance of Tumor Changes

Video

In this video we discuss a large-scale genomic analysis that found that patterns of genetic changes detected in circulating tumor DNA mirror those identified in tumor tissue biopsies.

A large-scale genomic analysis has found that patterns of genetic changes detected in circulating tumor DNA mirror those identified in tumor tissue biopsies. The study looked at blood samples from more than 15,000 patients and 50 different tumor types and paired them with nearly 400 tissue biopsies that had undergone genetic testing.

Results of the study (abstract 11501) were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. Here, Philip C. Mack, PhD, of the University of California Davis Comprehensive Cancer Center, who presented the data at the meeting, discusses results of the analysis.

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content